O-032 Treatment outcomes for ARUBA eligible brain arteriovenous malformations: a comparison of real world data from the NVQI-QOD AVM registry to the ARUBA trial

ConclusionARUBA eligible patients from the NVQI-QOD registry demonstrate a significantly lower risk of stroke or death with intervention of 8.0% (N=174) compared to the 30.7% (N=114) ARUBA trial interventional risk, and is nearly equivalent to the ARUBA trial medical management risk of 10.1% (N=109) over 33 months.Disclosures N. Moore: 1; C; SNIS Joe Niekro Research Grant. R. Abdalla: None. T. Patterson: None. Y. Moazeni: None. P. Rasmussen: 2; C; Blockade Medical, Covidien/Medtronic, Stryker Neurovascular, Perflow Medical. 4; C; Perflow Medical. G. Toth: None. M. Bain: 2; C; Stryker Neurovascular. S. Ansari: None. S. Hussain: 2; C; Pulsar Inc.

Source: Journal of NeuroInterventional Surgery - July 26, 2021 Category: Neurosurgery Authors: Moore, N., Abdalla, R., Patterson, T., Moazeni, Y., Rasmussen, P., Toth, G., Bain, M., Ansari, S., Hussain, S. Tags: Oral abstracts Source Type: research